Nepadutant

Chemical compound
  • None
Pharmacokinetic dataBioavailability<3% (oral)[1]Elimination half-life44 minutes (IV)[1]Identifiers
  • (2S)-2-[[(3S,6S,9S,12S)-12-[[(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid
CAS Number
  • 183747-35-5
PubChem CID
  • 3086682
IUPHAR/BPS
  • 2123
ChemSpider
  • 2343247
UNII
  • XW59TYL1XH
Chemical and physical dataFormulaC45H60N10O14Molar mass965.031 g·mol−13D model (JSmol)
  • Interactive image
  • CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)Cc2ccccc2)Cc3c[nH]c4c3cccc4)NC(=O)[C@H](CC(=O)N[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)NC(=O)C)N
InChI
  • InChI=1S/C45H60N10O14/c1-21(2)13-31(45(67)68)53-43(66)32-19-48-34(58)17-30(50-39(62)26(46)16-35(59)55-44-36(49-22(3)57)38(61)37(60)33(20-56)69-44)42(65)52-29(15-24-18-47-27-12-8-7-11-25(24)27)41(64)51-28(40(63)54-32)14-23-9-5-4-6-10-23/h4-12,18,21,26,28-33,36-38,44,47,56,60-61H,13-17,19-20,46H2,1-3H3,(H,48,58)(H,49,57)(H,50,62)(H,51,64)(H,52,65)(H,53,66)(H,54,63)(H,55,59)(H,67,68)/t26-,28-,29-,30-,31-,32-,33+,36+,37+,38+,44+/m0/s1
  • Key:NPSVXOVMLVOMDD-SXRVEDALSA-N

Nepadutant (INN) (code name MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK2 receptor antagonist.[2][3][4] It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.[3][5][6]

See also

References

  1. ^ a b c Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1999. pp. 56–. ISBN 978-0-08-058378-5.
  2. ^ a b Holzer P (17 June 2004). Tachykinins. Springer. pp. 224–226. ISBN 978-3-540-20690-3.
  3. ^ a b Regitz-Zagrosek V (2 October 2012). Sex and Gender Differences in Pharmacology. Springer Science & Business Media. pp. 489–. ISBN 978-3-642-30726-3.
  4. ^ Royal Society of Chemistry (Great Britain) (January 2003). Amino Acids, Peptides and Proteins. Royal Society of Chemistry. ISBN 978-0-85404-242-5.
  5. ^ Frank B (29 June 2011). Women's Issues in Gastroenterology, An Issue of Gastroenterology Clinics. Elsevier Health Sciences. pp. 54–55. ISBN 978-1-4557-1220-5.
  6. ^ Jancso G (27 November 2008). Neurogenic Inflammation in Health and Disease. Elsevier. pp. 297–. ISBN 978-0-444-53229-9.


  • v
  • t
  • e
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium
compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)Propulsives
  • v
  • t
  • e
Adrenergics, inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthine PDE4 inhibitors
Others/unknown
Combination products
  • v
  • t
  • e
NK1
NK2
NK3


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e